Breast cancer that has spread, or metastasized, to the lungs presents a particularly challenging scenario for patients. New research published in Cancer Research Communications sheds light on a surprising way the cancer cells thrive in this new environment: by hijacking the lung’s natural healing processes. This discovery, made by scientists at the University of Colorado Anschutz Medical Campus, not only explains how metastatic breast cancer establishes itself in the lungs but also points to a potential therapeutic strategy using an existing anti-inflammatory drug.
For decades, researchers have understood that cancer cells exploit normal biological processes to grow and spread. This latest work reveals a sophisticated mechanism where breast cancer cells essentially trick the lungs into chronically attempting repair, creating a fertile ground for tumor development. Understanding this interaction could be a pivotal step in improving outcomes for the roughly one-third of patients with metastatic breast cancer who develop lung tumors, a group for whom treatment options are often limited.
How Breast Cancer Cells Manipulate Lung Repair
When breast cancer cells travel to the lungs, they inevitably cause some degree of damage to the delicate air sacs, known as alveoli, responsible for oxygen exchange. Normally, the lungs initiate a swift repair response, mobilizing specialized cells to heal the injured tissue. However, researchers found that metastatic breast cancer cells interfere with this process, preventing it from reaching completion. Instead of resolving the damage, the cancer cells maintain the lung in a perpetual state of attempted repair, triggering chronic inflammation.
A key player in this manipulation is the alveolar type II cell, responsible for producing surfactant—a substance that keeps the alveoli open—and for regenerating lung tissue. The study revealed that in the presence of breast cancer cells, these alveolar type II cells commence releasing signals that actively encourage tumor expansion. “The lung is doing what We see designed to do and that is to clear debris and repair damage,” explained Dr. Jessica Christenson, first author of the study and an instructor in the Department of Pathology at CU Anschutz. “But in this case cancer cells are taking advantage of that repair response.”
A Vicious Cycle of Communication
The research team uncovered a two-way communication system between the cancer cells and the lung cells. The tumor cells initiate the lung’s repair mechanisms and in turn, the activated lung cells release substances that further fuel cancer growth. This creates a harmful feedback loop, allowing the metastatic tumors to establish themselves and proliferate within the lungs. This cycle isn’t simply a passive exploitation of the lung’s natural functions; it’s an active manipulation of the cellular environment to benefit the cancer.
Roflumilast: A Potential Therapeutic Intervention
To investigate whether this damaging cycle could be disrupted, the researchers tested roflumilast, an existing drug approved by the Food and Drug Administration for the treatment of chronic obstructive pulmonary disease (COPD). The FDA details roflumilast’s mechanism as a phosphodiesterase-4 (PDE4) inhibitor, reducing inflammation in the lungs. In mouse models of metastatic breast cancer, roflumilast demonstrably slowed tumor growth and reduced the size of lung tumors.
Importantly, roflumilast didn’t directly kill the cancer cells. Instead, it appeared to alter the lung environment, making it less hospitable for tumor development. “This suggests a new strategy for treating metastatic cancer,” said Dr. Jennifer Richer, senior author of the study and Professor of Pathology at the CU Anschutz Cancer Center. “In addition to targeting cancer cells themselves, we may also be able to target the environment that allows them to thrive.” This approach, known as targeting the tumor microenvironment, is gaining increasing attention in cancer research.
Implications for Triple-Negative Breast Cancer
The findings are particularly relevant for patients with triple-negative breast cancer, an aggressive subtype that lacks the common receptors targeted by many existing therapies. Triple-negative breast cancer has a higher propensity to metastasize to the lungs, and treatment options are often limited. The researchers are now focused on evaluating roflumilast as a potential preventative treatment for triple-negative breast cancer patients at high risk of lung recurrence.
“We are very excited to translate these findings to the clinic and evaluate roflumilast as a treatment for patients with triple-negative breast cancer to prevent recurrence in the lungs,” said Jennifer Diamond, MD, Professor of Medical Oncology, Medical Director of the Cancer Clinical Trials Office at the CU Anschutz Cancer Center and a collaborator on the project. The team is also exploring combining roflumilast with existing treatments like chemotherapy and immunotherapy, and investigating inhaled formulations of similar drugs to deliver treatment directly to the lungs.
The next steps involve clinical trials to determine the safety and efficacy of roflumilast in breast cancer patients with lung metastasis. Researchers are also working to identify biomarkers that could help predict which patients are most likely to benefit from this approach. This research offers a glimmer of hope for improving the lives of individuals battling this devastating disease.
This article provides information for educational purposes only and is not a substitute for professional medical advice. If you have concerns about breast cancer or your health, please consult with a qualified healthcare provider.
Have you or a loved one been affected by metastatic breast cancer? Share your thoughts and experiences in the comments below.
